Drug | Target | Tumor diagnosis for clinical treatment application (PubMed) | Nr. of Significantly affected Metabolic Components in MCPM model | Nr. of affected metabolic / signaling pathways | Top 5 affected metabolic pathways (Nr. of significantly affected components within the pathway) |
---|---|---|---|---|---|
AEW541 | IGF1R, InsR | Testing phase, none specified (17361225) | 125 | 18 / 2 | Purine (19), Glycerolipid (10), Glycolysis (8), Amino-sugar (8), Sucrose (6) |
PF-2341066 (Crizotinib) | c-MET, ALK | Non-small cell lung cancer (23724913) | 1220 | 30 / 2 | Purine (250), Pyrimidine (114), Inositol-phosphate (62), Fatty-acid (48), Valine/Leucine/Isoleucine (41), Glycolysis (41) |
PHA-665752 | c-MET | Testing phase, none specified (14612533) | 445 | 24 / 1 | Purine (88), Inositol-phosphate (36), Pyrimidine (22), Glycolysis (20), Valine/Leucine/Isoleucine (18), Nicotinate (18) |
Sorafenib | ABL, AURKB/C, BRAF, CDK, DDR, EPHA, FGFR, FLT, KIT, MKNK, MAPK, NTRK | Renal cell, hepatocellular, and thyroid cancer (17215530) | 1058 | 30 / 10 | Purine (195), Pyrimidine (81), Inositol-phosphate (64), Valine/Leucine/Isoleucine (49), Pyruvate (45) |
TKI258 (Dovitinib) | FLT3, KIT, FGFR, VEGFR, InsR, EphA, HER2, IGF1R | Testing phase, none specified (23658459) | 1109 | 28 / 9 | Purine (225), Pyrimidine (111), Fatty-acid (59), Inositol-phosphate (53), Glycolysis (47), Pyruvate (47) |
Lapatinib | EGFR, ERBB2/4, STK10, PIRK2 | Breast cancer (18188694) | 504 | 28 / 7 | Purine (82), Pyrimidine (33), Nicotinate (31), Fatty-acid (25), Glycerolipid (22) |
ZD6474 (Vandetanib) | EGFR, ERBB2/4, FGFR, ABL, EPHA/B | Thyroid cancer (26678514) | 158 | 27 / 8 | Valine/Leucine/Isoleucine (17), Purine (15), Butanoate (11), Pentose (8), Pyrimidine (7) |
Erlotinib | EGFR, ABL1, FLT3/4, RET, KIT, RET, SLK, PDGFRA/B, others | Non-small cell lung and pancreatic cancer (21388312) | 245 | 23 / 15 | Purine (50), Fatty-acid (12), Nicotinate (12), Glycolysis (11), Fructose (11) |